Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients

International Journal of Cancer

Volumn 136, Issue 1, 2015, Pages 138-151

  Zörnig, Inka ^a   Halama, Niels ^a   Lorenzo Bermejo, Justo ^b   Ziegelmeier, Claudia ^a   Dickes, Elke ^c   Migdoll, Alexander ^a   Kaiser, Iris ^a   Waterboer, Tim ^c   Pawlita, Michael ^c   Grabe, Niels ^a   Ugurel, Selma ^d   Schadendorf, Dirk ^e   Falk, Christine ^f   Eichmüller, Stefan B ^c   Jäger, Dirk ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

malignant melanoma; multiplex analysis; prognosis; serum antibodies; tumor associated antigens

Indexed keywords

CAMEL ANTIGEN; CT47 ANTIGEN; CYCLIN B1; GAGE7B ANTIGEN; GLYCOPROTEIN GP 100; LAGE1A ANTIGEN; MAGE A9; MELAN A; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; MONOPHENOL MONOOXYGENASE; MUCIN 1; NY ESO 1 ANTIGEN; OY TES 1 ANTIGEN; PROTEIN P16; PROTEIN P53; RAB38 ANTIGEN; RECOVERIN; RETINA S ANTIGEN; RHODC ANTIGEN; RHODE2 ANTIGEN; RHODN ANTIGEN; SPANXA1 ANTIGEN; SSX2 ANTIGEN; SSX4 ANTIGEN; SURVIVIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BIOASSAY; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; MULTIPLEX ASSAY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REPRODUCIBILITY; SURVIVAL RATE; SURVIVAL TIME; ANTIBODY PRODUCTION; BLOOD; CASE CONTROL STUDY; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SKIN TUMOR; YOUNG ADULT;

ADULT; AGED; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84925286355     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28980     Document Type: Article

References (39)

1. Hauschild A, Weichenthal M, Rass K, et al., Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. J Clin Oncol 2009; 27: 3496-502.
2. Halama N, Zoernig I, Jaeger D,. Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. J Oncol 2010; 2010: 689893.
3. Gogas H, Ioannovich J, Dafni U, et al., Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-18.
4. Jager D, Filonenko V, Gout I, et al., NY-BR-1 is a differentiation antigen of the mammary gland. Appl Immunohistochem Mol Morphol 2007; 15: 77-83.
5. Jager D, Karbach J, Pauligk C, et al., Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. Cancer Immun 2005; 5: 11.
6. Jager D, Stockert E, Gure AO, et al., Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res 2001; 61: 2055-61.
7. Jager E, Chen YT, Drijfhout JW, et al., Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187: 265-70.
8. Jager E, Gnjatic S, Nagata Y, et al., Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000; 97: 12198-203.
9. Jager E, Jager D, Knuth A,. Antigen-specific immunotherapy and cancer vaccines. Int J Cancer 2003; 106: 817-20.
10. Scanlan MJ, Welt S, Gordon CM, et al., Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002; 62: 4041-7.
11. Bazhin AV, Wiedemann N, Schnolzer M, et al., Expression of GAGE family proteins in malignant melanoma. Cancer Lett 2007; 251: 258-67.
12. Ding M, Beck RJ, Keller CJ, et al., Cloning and analysis of MAGE-1-related genes. Biochem Biophys Res Commun 1994; 202: 549-55.
13. Hartmann TB, Bazhin AV, Schadendorf D, et al., SEREX identification of new tumor antigens linked to melanoma-associated retinopathy. Int J Cancer 2005; 114: 88-93.
14. Bouwhuis MG, Suciu S, Collette S, et al., Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 2009; 101: 869-77.
15. Bouwhuis MG, Suciu S, Testori A, et al., Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies-EORTC 18991. J Clin Oncol 2010; 28: 2460-6.
16. Waterboer T, Sehr P, Michael KM, et al., Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. Clin Chem 2005; 51: 1845-53.
17. Waterboer T, Sehr P, Pawlita M,. Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 2006; 309: 200-4.
18. Meschede W, Zumbach K, Braspenning J, et al., Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol 1998; 36: 475-80.
19. Sehr P, Zumbach K, Pawlita M,. A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods 2001; 253: 153-62.
20. Rousseeuw PJ, Croux C,. Alternatives to the median absolute deviation. J Am Stat Assoc 1993; 88: 1273-83.
21. Team RDC. R: a language and environment for statistical computinged. Vienna: Austria, 2009. 409.
22. Gnjatic S, Ritter E, Buchler MW, et al., Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci USA 2010; 107: 5088-93.
23. Usener D, Gerhardt A, Schadendorf D, et al., Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients. Br J Dermatol 2003; 149: 282-8.
24. Scanlan MJ, Simpson AJ, Old LJ,. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004; 4: 1.
25. Eichmuller S, Usener D, Dummer R, et al., Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci USA 2001; 98: 629-34.
26. Bazhin AV, Dalke C, Willner N, et al., Cancer-retina antigens as potential paraneoplastic antigens in melanoma-associated retinopathy. Int J Cancer 2009; 124: 140-9.
27. Barrow C, Browning J, MacGregor D, et al., Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 2006; 12: 764-71.
28. Wandall HH, Blixt O, Tarp MA, et al., Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res 2010; 70: 1306-13.
29. Nolen B, Winans M, Marrangoni A, et al., Aberrant tumor-associated antigen autoantibody profiles in healthy controls detected by multiplex bead-based immunoassay. J Immunol Methods 2009; 344: 116-20.
30. Houbiers JG, van der Burg SH, van de Watering LM, et al., Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 1995; 72: 637-41.
31. Ohshio G, Suwa H, Imamura M,. Clinical implication of anti-p53 antibodies and p53-protein in pancreatic disease. Int J Gastrointest Cancer 2002; 31: 129-35.
32. Schoenfeld J, Jinushi M, Nakazaki Y, et al., Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res 2010; 70: 10150-60.
33. Harlin H, Meng Y, Peterson AC, et al., Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69: 3077-85.
34. Willimsky G, Czeh M, Loddenkemper C, et al., Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med 2008; 205: 1687-700.
35. Willimsky G, Blankenstein T,. The adaptive immune response to sporadic cancer. Immunol Rev 2007; 220: 102-12.
36. Andreu P, Johansson M, Affara NI, et al., FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010; 17: 121-34.
37. Eggermont AM,. Therapeutic vaccines in solid tumours: can they be harmful? Eur J Cancer 2009; 45: 2087-90.
38. Eggermont AM, Suciu S, Rutkowski P, et al., Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J Clin Oncol 2013; 31: 3831-7.
39. Morton D, Mozzillo N, Thomspson J, et al., Elasthoff MMAIT Clinical Trials Group R: an international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites J Clin Oncol 2007; 25.